Kyle Gano - 31 Jan 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Executive Officer, Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
31 Jan 2026
Net transactions value
-$214,975
Form type
4
Filing time
03 Feb 2026, 18:03:58 UTC
Previous filing
20 Jan 2026
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gano Kyle Chief Executive Officer, Director 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 03 Feb 2026 0001567160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2,927 +2.1% $0.000000 143,334 31 Jan 2026 Direct
transaction NBIX Common Stock Tax liability $214,975 -1,580 -1.1% $136.06 141,754 31 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2,927 -100% $0.000000 0 31 Jan 2026 Common Stock 2,927 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award.